4-Star Stocks Poised to Pop: Immucor

• Email
• Share
• Print

Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, blood-testing products maker Immucor (Nasdaq: BLUD) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Immucor's business and see what CAPS investors are saying about the stock right now.

Immucor facts

Headquarters (founded)	Norcross, Ga. (1982)
Market Cap	$1.1 billion
Industry	Health Care Supplies
Trailing-12-Month Revenue	$290.1 million
Management	CEO Gioacchino DeChirico (since 2006) CFO Richard Flynt (since 2007)
Return on Equity (average, last three years)	28.7%
Cash/Debt	$113.4 million/$0
Competitors	Meridian Bioscience (Nasdaq: VIVO) Bio-Rad Labs (NYSE: BIO)
CAPS Members Bullish on BLUD Also Bullish on	Johnson & Johnson (NYSE: JNJ) General Electric (NYSE: GE)
CAPS Members Bearish on BLUD Also Bearish on	Palm (Nasdaq: PALM) MBIA (NYSE: MBI)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS.

Over on CAPS, fully 547 of the 570 members who have rated Immucor -- some 96% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Star tenmiles, the sixth-ranked player in all of CAPS, and Weequay2.

Just last month, tenmiles tapped Immucor as a bloody good deal:

Large short position in company recently drove it down from $30 range ... Financial flexible company -- debt free with healthy ROE and reasonable forward P/E. Longer term play on healthcare efficiency from diagnostic testing improvements. Looks pretty cheap in here long term in the mid-teens.

In a pitch from later that day, weequay2 agrees on the stock being a bloodied and bruised bargain:

Siding with tenmiles and others on the positive financial aspects of this company. Also the recent sell off and 15% drop open up an even better buying window. [Immucor] was hit hard by the [Department of Justice] investigation and then hit again in June by the FDA threatening to revoke their ability to sell their blood reagents. I think that the market over reacted to the FDA news on top already low prices. [Immucor] says they have been working to fix the quality issues related to the FDA for some time now.

What do you think about Immucor, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.